Paroxysmal Hemoglobinuria, Nocturnal
Conditions
Brief summary
This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of crovalimab will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of crovalimab will be evaluated in participants with paroxysmal nocturnal hemoglobinuria (PNH) in parts 2, 3, 4, and OLE of the study. Efficacy of crovalimab will be evaluated in Parts 2, 3, and 4.
Interventions
DRUGCrovalimab
Crovalimab will be administered as per schedule described in individual arm.
DRUGPlacebo
Placebo will be administered as per schedule described in Part 1 placebo arm.
Sponsors
Hoffmann-La Roche
Chugai Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Part 1 (HVs only): * Healthy male volunteers, aged between 21 and 55 years inclusive * Participants with a negative hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody, and human immunodeficiency virus (HIV) test result * Participants who have been vaccinated against hepatitis B * No evidence of Neisseria meningococci in nasopharyngeal swab * Neisseria meningitidis vaccination against serogroups B and A, C, W, and Y * Non-smokers, or former smokers, who have not smoked for at least 60 days prior to screening Parts 2, 3 and 4 (PNH participants only): * Male or female participants with PNH between 18 and 75 years of age * Neisseria meningitidis vaccination in accordance with most current local guidelines or standard of care (SOC) for participants at increased risk for meningococcal disease (Part 2 and 4) * Participant has been vaccinated with Neisseria meningitidis vaccine(s) in accordance with most current local guidelines or SOC for participants at increased risk for meningococcal disease or is being revaccinated if applicable (Part 3 and 4) * Antibiotic prophylaxis for meningococcal infection must be initiated prior to initiation of crovalimab therapy if the time period between initial Neisseria meningitidis vaccination and first dose of crovalimab is less than 2 weeks (Part 2 and 4) * Antibiotic prophylaxis of meningococcal infection may be initiated prior to initiation of crovalimab therapy based on local guidelines or SOC for participants at increased risk for meningococcal disease e.g., splenectomized patients (Parts 2 and 4) * Stable dose for greater than or equal to (\>/=) 28 days prior to screening of other therapies (immunosuppressant therapy, corticosteroids, iron supplements) Part 2 and 4 (currently untreated PNH participants who are candidates for treatment with complement inhibitors only): * PNH participants who have not been treated with any complement inhibitor or if previously treated stopped treatment due to lack of efficacy based on a single missense C5 heterozygous mutation * Serum LDH levels at least 1.5-fold above the ULN at screening * Hepatitis B participants can be enrolled if their liver function test values are less than 2 x ULN and there is no liver function impairment Part 3 and 4 (PNH participants currently treated with eculizumab only): * PNH participants who have been treated continuously with eculizumab for at least 3 months preceding enrollment in the trial * Participants receive regular infusions of eculizumab * Subjects with a negative hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody, and HIV test result OLE only - PNH participants: * PNH participants who have completed Parts 2, 3 and 4 respectively * PNH participants who derived, in the investigator's opinion, benefit from treatment with crovalimab * Vaccination currency for Neisseria meningitidis serotypes A, C, W, Y and B should be maintained throughout the OLE All Parts: * Female participants should use proper means of contraception
Exclusion criteria
Part 1 (HVs only): * Any clinically relevant history or the presence of moderate to severe respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, or connective tissue disease * Any major illness within 1 month before the screening * Prior splenectomy * History of clinically significant hypersensitivity (example: drugs, excipients) or allergic reactions * History or presence of clinically significant electrocardiogram (ECG) abnormalities or cardiovascular disease * Any contra-indication for receiving Neisseria meningitides vaccination and antibiotic prophylaxis therapy as required in the study * Congenital or acquired complement deficiency * Carriers of Neisseria meningitides based on cultures from nasopharyngeal swabs * Known active viral, bacterial or fungal infection including herpes, herpes zoster or cold sores, during the last 14 days prior to first study drug administration * Signs of parasitic infection (example: eosinophilia, diarrhea) * History of significant recurrent infections in the opinion of the investigator Parts 2, 3 and 4 - PNH participants only: * Evidence of moderate to severe concurrent renal, liver, cardiac, pulmonary or gastrointestinal disease not related to PNH as determined by the investigator * History of an illness that, in the opinion of the study investigator, might confound the results of the study or that poses an additional risk to the participant by his or her participation in the study * History of bone marrow transplantation * Treatment with azathioprine or erythrocyte-stimulating agents within 14 days prior to first study drug administration * Splenectomy \<1 year before start of crovalimab. Part 3 and 4 - PNH patients only: * Any evidence of sero-positive auto-immune connective tissue diseases (such as systemic lupus erythematosus, or rheumatoid arthritis) * Any evidence of active inflammatory conditions (including inflammatory bowel disease, or cryoglobulinemia) All Parts: * Under active therapy with intravenous immunoglobulin (IVIG) * Mentally incapacitated or history of a clinically significant psychiatric disorder over the previous 5 years * Known or suspected hereditary complement deficiency * History of meningococcal meningitis * History of allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies or known hypersensitivity to any constituent of the product * Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 28 days prior to screening or oral antibiotics within 2 weeks prior to screening and up to first study drug administration * History of or currently active primary or secondary immunodeficiency, including known history of human immunodeficiency virus (HIV) infection * Evidence of chronic active hepatitis C infection * Evidence of malignant disease including myelodysplastic syndrome, or malignancies diagnosed within the previous 5 years * Pregnant or breastfeeding, or intending to become pregnant during the study, including the OLE period, within 46 weeks (approximately 10.5 months) after the final dose of crovalimab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 2: Percentage of Participants With AEs and SAEs | Baseline up to approximately 8 months |
| Part 3: Percentage of Participants With AEs and SAEs | Baseline up to approximately 8 months |
| Part 4: Percentage of Participants With AEs and SAEs | Baseline up to approximately 8 months |
| Part 2: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA) | Baseline up to Day 224 |
| Part 3: Terminal Complement Activity as Assessed by Ex Vivo Liposome Lysis in Serum Using the LIA | Baseline up to Day 224 |
| Part 4: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA) | Baseline up to Day 224 |
| OLE: Percentage of Participants With AEs and SAEs | OLE: Week 21 up to Week 567 |
| Part 1: Percentage of Participants With Dose-Limiting Events (DLEs) | Baseline up to approximately 3 months |
| Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Baseline up to approximately 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Part 4: Serum LDH Levels | Part 4: Predose (Hour 0), Hour 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 43, 57, 85, 113, 134; Day 224 |
| Part 1: Total Complement Component 5 (C5) Concentration | Part 1: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91 |
| Part 2: Total C5 Concentration | Part 2: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 10-12 on Day 1; Days 2, 5, 9, 15, 29, 224; predose [Hour 0], EOI [1 Hour], Hours 10-12 on Days 8, 22; predose [Hour 0] on Days 36, 43, 50, 64, 78, 92, 106, 120, 134 |
| Part 3: Total C5 Concentration | Part 3: Predose (Hour 0), EOI (1 Hour), Hours 2 and 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 106; Day 224 |
| Part 4: Total C5 Concentration | Part 4: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 57, 85, 113; Days 43, 134, 224 |
| Part 1: Free C5 Concentration | Part 1: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91 |
| Part 2: Free C5 Concentration | Part 2: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 10-12 on Day 1; Days 2, 5, 9, 15, 29, 224; predose [Hour 0], EOI [1 Hour], Hours 10-12 on Days 8, 22; predose [Hour 0] on Day 36, 43, 50, 64, 78, 92, 106, 120, 134 |
| Part 3: Free C5 Concentration | Part 3: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 106; Day 224 |
| Part 4: Free C5 Concentration | Part 4: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 57, 85, 113; Days 43, 134, 224 |
| Part 2: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score at Day 64 | Baseline, Day 64 |
| Part 3: Change From Baseline in Fatigue as Measured by FACIT-Fatigue Scale Score at Day 8, 22, 50, 78, 106, and 134 | Baseline, Day 8, 22, 50, 78, 106, 134 |
| Part 4: Change From Baseline in Fatigue as Measured by FACIT-Fatigue Scale Score at Day 8, 22, 57, 85, 113 and 134 | Baseline, Day 8, 22, 57, 85, 113, 134 |
| Part 2: Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 64 | Baseline, Day 64 |
| Part 3: Change From Baseline in HRQoL as Measured by EORTC QLQ-C30 Score at Day 78 and 134 | Baseline, Day 78, 134 |
| Part 4: Change From Baseline in HRQoL as Measured by EORTC QLQC30 Score at Day 85 and 134 | Baseline, Day 85, 134 |
| Part 2: Participant Treatment Satisfaction as Measured by Treatment Satisfaction Questionnaire for Medication (TSQM) Score at Day 8, 22, 36, 50 and 64 | Baseline, Day 8, 22, 36, 50, 64 |
| Part 3: Participant Treatment Satisfaction as Measured by TSQM Score at Day 8 and 50 | Baseline, Day 8, 50 |
| Part 4: Participant Treatment Satisfaction as Measured by TSQM Score at Day 8 and 57 | Baseline, Day 8, 57 |
| Part 2: Number of Packed Red Blood Cell (RBC) Units Transfused per Participant | Baseline up to Day 224 |
| Part 3: Number of Packed RBCs Units Transfused per Participant | Baseline up to Day 224 |
| Part 4: Number of Packed RBCs Units Transfused per Participant | Baseline up to Day 224 |
| Part 2: Percentage of Participants With Packed RBC Units Transfused | Baseline up to Day 224 |
| Part 3: Percentage of Participants With Packed RBC Units Transfused | Baseline up to Day 224 |
| Part 4: Percentage of Participants With Packed RBC Units Transfused | Baseline up to Day 224 |
| Part 1: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab | Part 1: Day 1 up to Day 91 (assessed at predose [Hour 0] on Day 1; on Days 14, 28, 56, 84, and 91) |
| Part 2: Percentage of Participants With ADAs to Crovalimab | Part 2: Day 1 up to Day 224 (assessed at predose [Hour 0] on Days 1, 8, 50, 106, 134); Days 29, 224 |
| Part 3: Percentage of Participants With ADAs to Crovalimab | Part 3: Day 1 up to Day 106 assessed at predose [Hour 0] on Days 1, 8, 29, 64, and 106; Day 224 |
| Part 4: Percentage of Participants With ADAs to Crovalimab | Day 1 up to Day 224 (assessed at predose [Hour 0] on Days 1, 8, 29, 113); Days 134, 224 |
| OLE: Total C5 Concentration | OLE: Predose (Hour 0) on Week 36 up to Week 521 |
| OLE: Serum LDH Levels | OLE: Predose (Hour 0) on Week 28 up to Week 521 |
| OLE: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA) | OLE: Week 36 up to Week 521 |
| Part 2: Percentage of Participants With LDH Below Upper Limit of Normal (ULN) | Baseline up to Day 224 |
| Part 3: Percentage of Participants With LDH Below ULN | Baseline up to Day 224 |
| Part 4: Percentage of Participants With LDH Below ULN | Baseline up to Day 224 |
| Part 2: Percentage of Participants With Complement Suppression | Baseline up to Day 134 |
| Part 3: Percentage of Participants With Complement Suppression | Baseline up to Day 134 |
| Part 4: Percentage of Participants With Complement Suppression | Baseline up to Day 134 |
| Part 2: Monthly Rate of pRBC Transfusions per Participant | Baseline up to 10 years |
| Part 3: Monthly Rate of pRBC Transfusions per Participant | Baseline up to 10 years |
| Part 4: Monthly Rate of pRBC Transfusions per Participant | Baseline up to 10 years |
| Part 2: Proportion of Transfusion-Free Participants | Baseline up to 10 years |
| Part 3: Proportion of Transfusion-Free Participants | Baseline up to 10 years |
| Part 4: Annual Rate of Breakthrough Hemolysis (BTH) | Baseline up to 10 years |
| Part 4: Proportion of Transfusion-Free Participants | Baseline up to 10 years |
| Part 2: Annual Rate of Transfusion Avoidance per Participant | Baseline up to 10 years |
| Part 3: Annual Rate of Transfusion Avoidance per Participant | Baseline up to 10 years |
| Part 4: Annual Rate of Transfusion Avoidance per Participant | Baseline up to 10 years |
| Part 2: Annual Rate of Breakthrough Hemolysis (BTH) | Baseline up to 10 years |
| Part 1: Terminal Complement Activity as Assessed by Ex Vivo Liposome Immunoassay (LIA) | Part 1: Baseline up to Day 91 (assessed at predose [Hour 0], end of infusion [EOI] [1 Hour], Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91) |
| Part 2: Serum Lactate Dehydrogenase (LDH) Levels | Predose (Hour 0), Hours 10-12 on Days 1, 8; Days 2, 5, 9, 15, 22, 29, 36, 43, 50, 64, 78, 92, 106, 120, 134, 224 |
| Part 3: Annual Rate of Breakthrough Hemolysis (BTH) | Baseline up to 10 years |
| Part 3: Serum LDH Levels | Part 3: Predose (Hour 0), Hours 10-12 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 64, 78, 92, 106, 134; Day 224 |
Countries
France, Germany, Hungary, Italy, Japan, Netherlands, South Korea
Contacts
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed